Effectiveness of lung transplantation in patients with interstitial lung diseases by Stącel, Tomasz et al.
Effectiveness of Lung Transplantation in Patients With Interstitial Lung
Diseases
Tomasz Stącela, Mirosław Nęckia, Remigiusz Antonczyka, Magdalena Latosb, Maciej Urlika,
Joanna Kosciołekb, Angelika Kordylewska-Kubusb, Joanna Litewkab, Piotr Przybyłowskia,c,
Fryderyk Zawadzkia, Marta Wajda-Pokrontkaa, Krzysztof Pyrcd, Marian Zembalab, and Marek Ochmanb,*
aDepartment of Cardiac, Vascular, and Endovascular Surgery and Transplantology, Silesian Center for Heart Diseases in Zabrze,
Medical University of Silesia, Katowice, Poland; bDepartment of Cardiac, Vascular, and Endovascular Surgery and Transplantology,
Silesian Center for Heart Diseases in Zabrze, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland;
cChair of General Surgery, Jagiellonian University Medical College, Krakow, Poland; and dMałopolska Centre of Biotechnology,





Background. Interstitial lung diseases (ILDs) are a heterogeneous group of more than
200 diseases manifested by progressive exercise dyspnea, radiological lung changes, and
ventilation restrictive disorders. ILDs are the second most common indication for lung
transplantation (LTx). Our study group consisted of 139 patients who qualified for LTx at
the Silesian Center for Heart Diseases between 2004 and 2018. Of the 139, 92 patients died
while on the waiting list, and 47 patients underwent LTx. Medical records including lab-
oratory test results, spirometry, and the 6-minute walk test (6MWT) were analyzed to
determine eligibility for LTx. We also assessed quality of life post-LTx.
Results. Patients who qualified for LTx showed decreased values of parameters
measured by spirometry (43.69  19.05% of forced expiratory volume in the first second
[FEV1] and 43.07  20.55% of forced vital capacity [FVC] and severe desaturation during
the 6MWT (SpO2 ¼ 88.78% before 6-minute walk test and 73.23% after the test). After
LTx, longer distances were achieved in the 6MWT (235.47  159.57 m during
qualification vs 533.2  34.15 m 12 months after LTx) and increased values of
spirometry. On average, patients had stopped working 6 years prior to LTx.
Conclusion. There is no effective medical treatment for patients with end-stage ILDs.
Therefore, lung transplantation is a lifesaving procedure for patients that also extends
patients’ lives and improves their quality of life.*Address correspondence to Marek Ochman, Department of
Cardiac, Vascular, and Endovascular Surgery and Trans-
plantology, Silesian Center for Heart Diseases in Zabrze, Faculty
of Medical Sciences in Zabrze, Medical University of Silesia, ul.
Curie-Skłodowskiej 9, 41-800, Zabrze, Poland. E-mail:
ochmann@wp.plINTERSTITIAL lung diseases (ILDs) include more than200 diseases related to lung parenchyma. These disor-
ders are categorized under a common name due to similar
clinical and radiological features. Patients with ILDs have
reduced forced vital capacity (FVC) and reduced exercise
tolerance, both of which further decrease as the disease
progresses. There exist many different causes of ILDs,
including environmental exposure (asbestos, beryllium),
medications (eg, bleomycin, amiodarone, nitrofurantoin),
irradiation, and connective tissue and autoimmune disor-
ders [1]. The American Thoracic Society and European
Respiratory Society classify ILDs into 4 main groups: first,
those resulting from a known cause or associationAuthors. Published by Elsevier Inc. This is an open
le under the CC BY-NC-ND license (http://
mons.org/licenses/by-nc-nd/4.0/).
enue, New York, NY 10169
ion Proceedings, 52, 2143e2148 (2020)(medication, occupational exposures, soft tissues diseases);
second, idiopathic interstitial pneumonia; third, granulo-
matous ILDs (sarcoidosis, infections), and the fourth and
final group consists of rare forms of ILDs (histiocytosis,
neurofibromatosis) [2,3]. The most common disease in this0041-1345/20
https://doi.org/10.1016/j.transproceed.2020.03.050
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2144 STĄCEL, NĘCKI, ANTONCZYK ET ALclassification is idiopathic pulmonary fibrosis (IPF), part of
the idiopathic interstitial pneumonia group. A poor prog-
nosis and limited therapeutic options for patients with IPF
and other ILDs-end stages make lung transplantation (LTx)
the only suitable option to improve quality of life and pul-
monary function parameters [4]. Treatment choices and
prognosis differ among the various types of ILDs; therefore,
verifying the correct diagnosis is important. Nevertheless,
patients with ILDs still have a poor prognosis because of the
constant progression of fibrosis in the lungs [5,6]. The most
common systemic complications are pulmonary hyperten-
sion and right ventricle heart failure [7]. Our aim in this
study was twofold: first, to assess the pulmonary function of
patients with ILDs from Silesian Centre for Heart Diseases
at the time of qualification and at 3, 6, and 12 months after
LTx; and second, to evaluate quality of life scores after lung
transplantation.MATERIALS AND METHODS
This retrospective study assessed 139 patients who qualified for LTx
between 2004 and 2018 in the Lung Transplant Program of the
Silesian Centre for Heart Diseases. The study group included 92
patients (66.19%) who died while on the waiting list and 47 patientsTable 1. Basic Characteristics of ILD Patients D
Deceased P
Sex, men,% 5
Age at qualification, y 51.0
Time spending on waiting list, days 359







Hypersensitivity pneumonitis, % 1
Langerhans cell histiocytosis, %
Pneumoconiosis, %
Idiopathic pulmonary fibrosis, % 6
Lymphangioleiomyomatosis, %
Sarcoidosis, %
Total proteins, g/dL 7.23
Albumins, g/dL 4.08
Serum creatinine, mg/dL 0.76
GFR, mL/min/1.73 m2 104.6
Serum bilirubin, mg/dL 0.72
Aspartate transaminase, UI/L 23.5
Alanine transaminase, UI/L 24.73
6MWT distance, m 189.3
Borg’s scale 4.44
Desaturation after 6MWT 15.7
FEV1, % 44.97
FVC, % 42.52
Values are given as the mean  standard deviation; the differences are not statist
Abbreviations: 6MWT, 6-minute walk test; BMI, body mass index; DLT, double lung
capacity; GFR, glomerular filtration rate; ILDs, interstitial lung diseases; SLT, single lwho underwent LTx (33.81%). Patients included to the study suf-
fered from hypersensitivity pneumonitis (N ¼ 22; 5 after LTx),
Langerhans cell histiocytosis (N ¼ 5; 4 after LTx), pneumoconiosis
(N ¼ 12; 4 after LTx) idiopathic pulmonary fibrosis (N ¼ 86; 26
after LTx), lymphangioleiomyomatosis (N ¼ 4; 2 after LTx), and
sarcoidosis (N ¼ 10; 6 after LTx). Of the 47 transplanted patients,
15 patients underwent double lung transplantation, and 32 patients
underwent single lung transplantation. During the qualification
process, parameters of both groups of patients such as height (cm),
weight (kg), body mass index (BMI; kg/cm2), and time on the
waiting list (days) in addition to laboratory tests measuring nutri-
tional status (total protein [g/dL] and albumins [g/dL]), kidney
function (serum creatinine [mg/dL]), glomerular filtration rate
(GFR) (mL/min/1.73 m2) and liver function (total bilirubin (mg/
dL), aspartate transaminase (Ul/L), and alanine transaminase (UI/
L) were analyzed. Additionally, this study paper reported data of
pulmonary function tests such as the 6-minute walk test (6MWT;
distance [m]), Borg’s scale, desaturation after 6MWT, spirometry
(forced expiratory volume in the first second [FEV1] and forced
vital capacity [FVC]) during qualification to LTx. Laboratory and
pulmonary function tests were also assessed 3, 6, and 12 months
post-LTx. Survival in the transplanted group was estimated using
the Kaplan-Meier curve. Quality of life responses were compared
based on World Health Organization Quality of LifeeBref ques-
tionnaire (WHOQOLeBref) in addition to an employment ques-
tionnaire created by the authors.uring Qualification to Lung Transplantation
atients (N ¼ 92) Transplanted Patients (N ¼ 47)
5.43 74.47
4  9.52 46.8  10.68




1  9.31 170.94  7.73
 15.28 68.93  15.1







 0.79 7.35  1.03
 0.56 4.28  0.42
 0.19 0.83  0.23
6  36.45 100.33  25.53
 0.57 0.69  0.47
1  7.84 22.9  7
 20.23 22.98  14.34
 136.76 235.47  122.6
 1.78 3.33  1.61
1  9.26 15.55  8.76
 16.15 43.69  17.9
 15.01 43.07  19.5
ically significant.
transplantation; FEV1, forced expiratory volume in first second; FVC, forced vital
ung transplantation.
Table 2. One-Year Follow-up Data of Transplanted Patients With ILDs
Time After LTx
3 months 6 months 12 months
Total proteins, g/dL 6.85  0.9 6.76  0.62 7.03  0.17
Albumins, g/dL 4.08  0.46 4.11  0.56 4.57  0.2
Serum creatinine, mg/dL 1.59  0.58 1.85  0.75 1.89  0.62
GFR, mL/min/1.73 m2 53.45  19.77 46.9  18.48 41.6  12.12
Serum bilirubin mg/dL 0.48  0.34 0.41  0.16 0.48  0.20
Aspartate transaminase, UI/L 22.61  13.82 19.88  8.44 20.57  4.93
Alanine transaminase, UI/L 31.02  45.54 21.72  27.4 18.86  8.4
6MWT distance, m 481.47  57.25 497.89  36 533.2  34.15
Borg’s scale 2.31  2.68 2.18  2.41 2  2.2
Desaturation after 6MWT 7  6.16 5.64  4.25 3.54  3.03
FEV1, % 62.69  23.31 62.38  22.65 60.73  23.78
FVC, % 60.8  19.02 63.64  16.84 65.32  20.62
Values are given as the mean  standard deviation.
Abbreviations: 6MWT, 6-minute walk test; FEV1, forced expiratory volume in first second; FVC, forced vital capacity; GFR, glomerular filtration rate.
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Descriptive statistics of analyzed data were expressed as mean 
standard deviation. A Kaplan-Meier curve was used for presenta-
tion survival time after lung transplantation. Statistica 10.0 statis-
tical software (StatSoft Inc., Tulsa, Okla, United States) was used
for statistical analysis.RESULTS
Qualification Process
Between 2004 and 2018, 139 patients with ILDs were
qualified for LTx in Silesian Centre for Heart Diseases.
Basic characteristics, laboratory data, and pulmonary tests
data of all qualified patients are presented in Table 1. There
were 47 patients who underwent lung transplantation; the
remaining 92 died while on the waiting list. Transplanted
patients during qualification were higher and outweighed
the deceased patients (170.94  7.73 cm vs 166.01  9.31
cm, 68.93  15.1 kg vs 65.74  15.28 kg, respectively). IPF
and hypersensitivity pneumonia were most often qualified
diagnoses (65.22% and 18.48%). Deceased patients reached
46.17 meters less during the 6MWT than transplanted
patients (189.3  136.76 m vs 235.47  122.6 m) with similar
desaturation during the test (15.71  9.26 vs 15.55  8.76,
respectively). Spirometry revealed reduced values of FEV1
and FVC parameters in both groups.
Lung Transplantation
Among the 47 transplanted patients, most often diagnoses
were IPF and sarcoidosis. Follow-up data were collected in
Table 2. At the 1-year follow-up, the 6MWT results showed
great progression as compared to results at the time of
qualification and at 3, 6, and 12 months after trans-
plantation. More than a 2-fold increase was observed in the
distance between qualification time and 12 months after
LTx (235.47  159.57 vs 533.2  34.15m; Fig 1A). Borg’s
scale changed from 3.33  2.37 to 2  2.2 after 1 year (Fig
1B). Oxygen saturation results before and after the 6MWT
are presented in Fig 1C.At the time of qualification, transplanted patients ach-
ieved 43.69  19.05% of FEV1 and 43.07  20.55% of
FVC. During the 1-year surveillance period, the results of
both FEV1 and FVC improved. After 3, 6, and 12 months,
FVC increased as follows: 60.8  19.02%, 63.64  16.84%
and 65.32  20.62%. Values of FEV1 were also higher than
at the time of qualification. After 12 months, it had
increased to 65.32  23.78% (Figs 1D and 1E).
Survival time after lung transplantation was assessed by
Kaplan-Meier curve and is presented in Fig 2. Survival es-
timates after transplantation were 72%, 63%, and 60% at 1,
3, and 5 years.
Quality of life among the 20 transplanted patients was
assessed by the WHOQOLeBref questionnaire. Patients
obtained the following results: 26  4.28, 22.9  3.59, 11.3
 2.97, and 30.4  4.19 points in the somatic, psychological,
social, and environmental domain, respectively. On average,
patients had stopped working 6 years prior to LTx. In total,
20% of the patients were able to return to work following
LTx; the average time to return to work after LTx was 13.5
months.DISCUSSION
Lung transplantation is a viable method of treating patients
with end-stage ILDs. According to the registry of the In-
ternational Society of Heart and Lung Transplantation, the
median survival rate after LTx is 5.2 years for idiopathic
interstitial pneumonia (IIP) and 6.7 years for ILDs that are
not idiopathic interstitial pneumonia [8]. Mason et al
assessed that 1-, 3-, and 5-year survival rates among IPF
patients after lung transplantation with were 73%, 56%, and
44%, respectively [9]. Kern et al evaluated the survival rate
among hypersensitivity pneumonitis (96%, 89%, and 89%)
vs idiopathic pulmonary fibrosis (86%, 67%, and 49%) after
transplantation at the same intervals after transplantation
[10]. A team from France published a study about the sur-
vival rate after LTx among Langerhans cell histiocytosis
with the following results: 76.9%, 63.6%, and 57.2% at 1, 2,
Fig 1. Results of the 6-minute walk test (A, B, C) and spirometry (D and E) before and 3, 6, and 12 months after transplantation.
6MWT, 6-minute walk test; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
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Fig 2. Survival after lung trans-
plantation estimated by Kaplan-
Meier curve.
EFFECTIVENESS OF LUNG TRANSPLANTATION 2147and 5 years, respectively [11]. The results of our study are
similar (72%, 63%, and 60% at 1, 3, and 5 years) to the
results obtained by the cited studies. The difficulty in
drawing conclusions is the heterogeneity of the study group,
which includes patients with different interstitial lung
diseases.
In our lung transplantation program, 139 patients with
ILDs where qualified to LTx. Among these, only 47
(33.81%) underwent lung transplantation. The important,
essential component of every LTx is donor-recipient
matching. Patients with ILDs require downsizing of the
donor lungs because of a reduction of thoracic volume. In
Poland, the average height of men and women is 178.7 cm
and 165.1 cm, respectively, thereby increasing the odds of
taller patients to undergo a transplantation sooner [12]. The
mean height of patients who underwent LTx was 170.94 cm;
they were almost 5 cm taller than the deceased patients. The
average height of donors who reported to our center was
171.38 cm.
Results of a pulmonary function test achieved by patients
with end-stage lung diseases during qualification process is
associated with the primary diagnosis.
In a single-center study, spirometry and 6MWT data were
assessed among candidates with cystic fibrosis (CF) at
qualification and during 12 months of follow-up after LTx
[13]. Results of spirometry parameters in analyzed popula-
tion increased: FEV1 from 21.13% at the time of qualifi-
cation to 76.67% at 12 months after LTx and FVC from
34.18% at the time of qualification to 78.34% at 12 months
after LTx. Distance in the 6MWT before LTx and after 12
months was extended by 175.55 m (from 377.65 m to 553.2
m) among CF patients. Comparing these results, patients
with ILDs reached almost 298 m longer distance after the
1-year outcome (from 235.47 m to 533.2 m) but obtainedlower improvement in spirometry: FEV1 from 43.69% at
the time of qualification to 65.32% at 12 months after LTx
and FVC from 65.32% at the time of qualification to
78.34% at 12 months after LTx. Despite the greater increase
in distance in the 6MWT in patients with ILDs, the
endpoint after 12 months of follow-up is like that of CF
patients. The difference worth noting is the results of
spirometry after 12 months of observation. Patients with CF
always (with a few exceptions) receive a transplant of both
lungs, which is not observed in patients with ILD. In addi-
tion, during donor-recipient matching, up-sizing should be
done for CF patients, and downsizing should be done for
patients with ILDs.
A subjective assessment of the quality of life by patients
with ILDs indicates an improvement in their perceived
quality of life following LTx. Results obtain in somatic
(26.93  4.68 points vs 15.79  2.23 points), psychological
(22.90  3.59 vs 13.79  2.51), and environmental (30.40 
4.19 vs 13.10  2.43) domains were higher than in the
healthy Polish population reported by Jaracz et al [14]. We
found lower scores in the social domain among transplanted
patients as compared to healthy responders (11.30  2.97
points vs 14.87  3.04 points). We speculate that this dif-
ference might be due to the long and multiple hospitaliza-
tions following surgery. Only 20% of transplanted patients
were able to successfully return to work; this could also
impact their assessment of their social life. The Interna-
tional Society of Heart and Lung Transplantation registry
reports than an even lower number of patients were able to
return to work 1 year post-LTx; their numbers indicate that
only 13.6% of patients returned to work following LTx [8].
Lutogniewska et al [15] assessed dyspnea among patients
with end-stage lung disease referred to lung transplantation
center for qualification to LTx. Dyspnea evaluated in Borg’s
2148 STĄCEL, NĘCKI, ANTONCZYK ET ALscale (after 6MWT) was 5.6  2.6 points among IPF pa-
tients and 6.6  1.8 points among patients with idiopathic
interstitial pneumonia. Comparing the results obtained in
our study (2.31  2.68 points, 2.18  2.41 points and 2  2.2
points after 3, 6, and 12 months post-LTx, respectively) to
the study cited above, we can conclude that after a lung
transplant, the subjective feeling of breathlessness (assessed
after the 6MWT) is significantly reduced.
CONCLUSIONS
There is no effective medical treatment for ILDs. There-
fore, lung transplantation is a lifesaving procedure for pa-
tients with ILD. LTx not only extends their lives but also
improves their quality of life.
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